SEPN
HealthcareSepterna, Inc.
$26.79
$-1.19 (-4.25%)
Jan 5, 2026
Price History (1Y)
Analysis
Septerna, Inc. is a biotechnology company within the healthcare sector. With a market capitalization of $1.20B and revenue of $22.05M, it operates on a relatively small scale, employing 75 individuals. The company's financial health is marked by significant losses, with a net income of -$58,809,000 and an EBITDA of -$87,901,000 in the trailing twelve months. Profitability metrics indicate substantial declines, including operating margins of -46.0% and profit margins of -266.8%. Returns on equity and assets are also negative, at -22.4% and -14.3%, respectively. The balance sheet presents a cash-heavy profile, with $474.35M in available funds against only $24.11M in debt. The company's valuation context is characterized by an extremely low forward P/E ratio of -74.69 and a price to book ratio of 3.08. Revenue growth has been substantial over the past year, increasing by 12113.1%. The absence of dividend payments means that no payout ratio can be calculated.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $1.20B
- P/E Ratio
- N/A
- 52-Week High
- $30.50
- 52-Week Low
- $4.17
- Avg Volume
- 324.61K
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 75